— Know what they know.
Not Investment Advice

IHE

iShares U.S. Pharmaceuticals ETF
1W: +1.8% 1M: +6.1% 3M: +4.9% YTD: +25.6% 1Y: +44.6% 3Y: +90.9% 5Y: +85.2%
Error: Binder Error: Contents of view were altered: types don't match! Expected [VARCHAR, VARCHAR, VARCHAR, DOUBLE, DOUBLE, DOUBLE, BIGINT, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, VARCHAR], but found [VARCHAR, VARCHAR, VARCHAR, DOUBLE, DOUBLE, DOUBLE, BIGINT, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, DOUBLE, BIGINT, VARCHAR] instead
ETF AMEX · AUM $1.2B

Portfolio Health Summary

IS Overall Score
61.1
★★★★★
Altman Z-Score
8.39
Safe
Weight Coverage
99%
of portfolio analyzed
Holdings Matched
51
with fundamental data

InsiderStreet Scorecard

★★★★★ 61.1
Profitability
65.9
Balance Sheet
56.6
Earnings Quality
63.0
Growth
54.6
Value
42.4
Momentum
73.0
Safety
83.4

Top Holdings: Score Breakdown

Risk & Quality Signals

Altman Z-Score
8.39
Safe Zone (>2.99)
Piotroski F-Score
6.1 / 9
Moderate
Beneish M-Score
-0.70
Possible Manipulator
Credit Score
—
Earnings Quality
63.0 / 100

Portfolio Valuation

P/E
44.24x
P/B
13.35x
P/S
9.48x
EV/EBITDA
27.23x
EV/Revenue
9.87x
P/FCF
43.95x
P/OCF
31.81x
PEG
1.93x
Earnings Yield
2.26%
FCF Yield
2.28%
OCF Yield
3.14%
Median P/E
-0.10x

Growth & Shareholder Returns

Year-over-Year Growth

Revenue +22.8%
Net Income +14.7%
EPS +16.0%
FCF +38.1%
EBITDA +26.6%
Op. Income —

Compound Growth Rates

Rev CAGR 3Y +20.8%
Rev CAGR 5Y +12.4%
EPS CAGR 3Y +22.9%
EPS CAGR 5Y +15.2%
FCF CAGR 3Y +6.6%
FCF CAGR 5Y +11.3%
EBITDA CAGR 3Y +23.8%
EBITDA CAGR 5Y +13.5%
Payout Ratio
62.26%
Buyback Yield
1.34%
Dividend Yield
1.47%
Total Shareholder Return
2.13%

Earnings Stability

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$106.61
Median 1Y
$119.57
5th Pctile
$86.30
95th Pctile
$165.70
Ann. Volatility
18.5%
25th–75th percentile 5th–95th percentile Median path Historical
All Ratios & Metrics
Valuation (12)
MetricValue
Portfolio P/E 44.24
Portfolio P/B 13.35
Portfolio P/S 9.48
EV/EBITDA 27.23
EV/Revenue 9.87
P/FCF 43.95
P/OCF 31.81
PEG 1.93
Earnings Yield 2.26%
FCF Yield 2.28%
OCF Yield 3.14%
Median P/E -0.10
Profitability & Returns (9)
MetricValue
Gross Margin 69.79%
Operating Margin 33.01%
Net Margin 21.34%
FCF Margin 21.55%
ROE 32.48%
ROA 11.65%
ROIC 25.06%
ROCE —
Asset Turnover —
Leverage & Solvency (6)
MetricValue
Debt/Equity 0.73
Debt/Assets 0.27
Net Debt/EBITDA 1.08
Interest Coverage 21.36
Current Ratio 1.24
Quick Ratio 0.91
Efficiency (4)
MetricValue
Asset Turnover —
Inventory Turnover —
Receivables Turnover —
Payables Turnover —
Growth — YoY (6)
MetricValue
Revenue Growth 22.76%
Net Income Growth 14.74%
EPS Growth 16.00%
FCF Growth 38.15%
EBITDA Growth 26.57%
Op. Income Growth —
Growth — CAGR (16)
MetricValue
Revenue CAGR 3Y 20.81%
Revenue CAGR 5Y 12.41%
Revenue CAGR 10Y —
EPS CAGR 3Y 22.95%
EPS CAGR 5Y 15.24%
EPS CAGR 10Y —
FCF CAGR 3Y 6.60%
FCF CAGR 5Y 11.28%
FCF CAGR 10Y —
EBITDA CAGR 3Y 23.78%
EBITDA CAGR 5Y 13.49%
EBITDA CAGR 10Y —
Net Income CAGR 3Y 21.23%
Net Income CAGR 5Y 14.34%
Op. Income CAGR 3Y —
Op. Income CAGR 5Y —
Quality Scores (13)
MetricValue
IS Overall 61.1
IS Profitability 65.9
IS Balance Sheet 56.6
IS Earnings Quality 63.0
IS Growth 54.6
IS Value 42.4
IS Momentum 73.0
IS Safety 83.4
IS Quality 72.1
Altman Z-Score 8.39
Piotroski F-Score 6.06
Beneish M-Score -0.70
Credit Score —
Dividends & Payout (4)
MetricValue
Dividend Yield 1.47%
Payout Ratio 62.26%
Buyback Yield 1.34%
Total Shareholder Return 2.13%
Growth Stability (4)
MetricValue
Revenue Stability 0.612
Earnings Stability 0.340
Earnings Persistence 0.705
Margin Stability 0.940
Medians (3)
MetricValue
Median P/E -0.10
Median P/B 2.73
Median Dividend Yield —
Coverage Meta (3)
MetricValue
Weight Coverage % 98.87%
Holdings Matched 51
Total Holdings 53

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms